Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 379 (9822), 1245-55

Hepatocellular Carcinoma

Affiliations
Review

Hepatocellular Carcinoma

Alejandro Forner et al. Lancet.

Abstract

Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. Patients with cirrhosis are at highest risk of developing this malignant disease, and ultrasonography every 6 months is recommended. Surveillance with ultrasonography allows diagnosis at early stages when the tumour might be curable by resection, liver transplantation, or ablation, and 5-year survival higher than 50% can be achieved. Patients with small solitary tumours and very well preserved liver function are the best candidates for surgical resection. Liver transplantation is most beneficial for individuals who are not good candidates for resection, especially those within Milano criteria (solitary tumour ≤5 cm and up to three nodules ≤3 cm). Donor shortage greatly limits its applicability. Percutaneous ablation is the most frequently used treatment but its effectiveness is limited by tumour size and localisation. In asymptomatic patients with multifocal disease without vascular invasion or extrahepatic spread not amenable to curative treatments, chemoembolisation can provide survival benefit. Findings of randomised trials of sorafenib have shown survival benefits for individuals with advanced hepatocellular carcinoma, suggesting that molecular-targeted therapies could be effective in this chemoresistant cancer. Research is active in the area of pathogenesis and treatment of hepatocellular carcinoma.

Comment in

Similar articles

  • Current Management of Hepatocellular Carcinoma
    M Mendizabal et al. Med Clin North Am 93 (4), 885-900, viii. PMID 19577120. - Review
    Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, continues to increase in incidence in several regions around the world and is associated with po …
  • Hepatocellular Carcinoma
    JM Llovet et al. Lancet 362 (9399), 1907-17. PMID 14667750. - Review
    Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of hepatitis B and C virus …
  • [New Surgical Approaches in the Treatment of Hepatocellular Carcinoma]
    K Hoffmann et al. Z Gastroenterol 47 (1), 61-7. PMID 19156593. - Review
    New advances in the treatment of HCC have emerged in recent years. The implementation of surveillance programmes has led to better diagnosis of HCC at early stages. Liver …
  • Hepatocellular Carcinoma
    A Forner et al. Lancet 391 (10127), 1301-1314. PMID 29307467. - Review
    Hepatocellular carcinoma appears frequently in patients with cirrhosis. Surveillance by biannual ultrasound is recommended for such patients because it allows diagnosis a …
  • Resection and Transplantation for Hepatocellular Carcinoma: Factors Influencing Surgical Options
    RM Dodson et al. Future Oncol 10 (4), 587-607. PMID 24754591. - Review
    The management of hepatocellular carcinoma within the Milan criteria and with well-compensated cirrhosis is a topic of debate. Recent surveillance programs in patients wi …
See all similar articles

Cited by 1,530 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback